BCM
YMAB

Burrage Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Burrage Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-114,454
Closed -$3.87M – 18
2021
Q2 		$3.87M Hold
114,454
– – 3.88% 12
2021
Q1 		$3.46M Sell
114,454
-508
-0.4% -$20.8K 2.8% 18
2020
Q4 		$5.69M Sell
114,962
-8,063
-7% -$373K 4.34% 9
2020
Q3 		$4.72M Hold
123,025
– – 3.73% 13
2020
Q2 		$5.32M Sell
123,025
-48,763
-28% -$1.84M 3.72% 13
2020
Q1 		$4.41M Sell
171,788
-14,961
-8% -$434K 4.34% 8
2019
Q4 		$5.84M Buy
+186,749
New +$5.53M 3.91% 10

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Burrage Capital Management's YMAB Position: Q3 2021 in Review

Burrage Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q3 2021, closing a stake of 114,454 shares — an estimated $3.87M sold.

Burrage Capital Management first reported a position in YMAB in Q4 2019 and held it in 7 quarters. The position peaked at $5.84M in Q4 2019. 97 funds tracked by Wall St. Rank hold YMAB as of Q3 2021.

  • Burrage Capital Management reported no remaining Y-mAbs Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Burrage Capital Management sold 114,454 Y-mAbs Therapeutics shares in Q3 2021, an estimated $3.87M.
  • Burrage Capital Management first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 7 quarters.
  • Burrage Capital Management's Y-mAbs Therapeutics position peaked at $5.84M in Q4 2019.
  • 97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2021.

Based on Burrage Capital Management's 13F filing for Q3 2021.